The funding will allow Achillion Pharmaceuticals to further advance its portfolio of HCV clinical candidates, as well as allow it to capitalise certain antibacterial assets.
Achillion senior vice president and chief financial officer Mary Kay Fenton said that they are delighted to be awarded these grants in a highly over-subscribed process.
"This award provides non-dilutive funding to help advance our unique therapies for patients with infectious disease," Fenton said.